These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 677138)

  • 21. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse-drug-reaction monitoring.
    Faich GA
    N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital.
    Murphy BM; Frigo LC
    Hosp Pharm; 1993 Dec; 28(12):1199-204, 1240. PubMed ID: 10130617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How pharmacists can speed new drug approval through ADR reporting.
    Kennedy D
    Pharm Times; 1978 Mar; 44(3):44-8. PubMed ID: 10307082
    [No Abstract]   [Full Text] [Related]  

  • 26. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
    Sivin I
    Obstet Gynecol; 1995 Aug; 86(2):318-20. PubMed ID: 7617371
    [No Abstract]   [Full Text] [Related]  

  • 27. Improving how we evaluate the toxicity of approved drugs.
    Reidenberg MM
    Clin Pharmacol Ther; 2006 Jul; 80(1):1-6. PubMed ID: 16815311
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug reaction alerts.
    Lee B; Groth PE
    Am J Hosp Pharm; 1977 Jul; 34(7):694-5. PubMed ID: 888832
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug reactions. The scene revisited--an update.
    Weston JK; Weston K
    Clin Toxicol; 1977; 10(1):129-48. PubMed ID: 858224
    [No Abstract]   [Full Text] [Related]  

  • 31. An evaluation of spontaneous adverse drug reaction monitoring systems.
    Sachs RM; Bortnichak EA
    Am J Med; 1986 Nov; 81(5B):49-55. PubMed ID: 3789003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The need for pharmacists' cooperation in national adverse drug reaction reporting.
    Lee B; Groth PE
    Hosp Formul; 1978 Nov; 13(11):888-91, 895. PubMed ID: 10239344
    [No Abstract]   [Full Text] [Related]  

  • 33. Silicone gel breast implant adverse event reports to the Food and Drug Administration, 1984-1995.
    Brown SL; Parmentier CM; Woo EK; Vishnuvajjala RL; Headrick ML
    Public Health Rep; 1998; 113(6):535-43. PubMed ID: 9847926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of US poison centers in adverse drug reactions monitoring.
    Chyka PA
    Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National adverse drug reaction surveillance. 1986.
    Faich GA; Dreis M; Tomita D
    Arch Intern Med; 1988 Apr; 148(4):785-7. PubMed ID: 3355297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse reaction reporting of interaction between warfarin and fluoroquinolones.
    Jolson HM; Tanner LA; Green L; Grasela TH
    Arch Intern Med; 1991 May; 151(5):1003-4. PubMed ID: 1842668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse drug reactions: the San Juan Department of Veterans Affairs Medical Center experience.
    Nazario M; Feliú JF; Rivera GC
    Hosp Pharm; 1994 Mar; 29(3):244-6, 249-50. PubMed ID: 10171808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program.
    Orr MS; Goodsaid F; Amur S; Rudman A; Frueh FW
    Clin Pharmacol Ther; 2007 Feb; 81(2):294-7. PubMed ID: 17259954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.